Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies

被引：0
|
作者：
Enrique Grande
Michael C. Kreissl
Sebastiano Filetti
Kate Newbold
Walter Reinisch
Caroline Robert
Martin Schlumberger
Lærke K. Tolstrup
Jose L. Zamorano
Jaume Capdevila
机构：
[1] Hospital Ramón y Cajal,Servicio de Oncología Médica
[2] University Hospital of Wuerzburg,Department of Nuclear Medicine
[3] Central Hospital of Augsburg,Department of Nuclear Medicine
[4] University of Rome “Sapienza”,Department of Internal Medicine and Medical Specialities
[5] Royal Marsden Hospital,Thyroid Unit
[6] Medical University of Vienna,Division of Gastroenterology and Hepatology, Department of Internal Medicine III
[7] University of Paris-Sud,Department of Medical Oncology, Dermatology Unit and INSERM U981, Gustave Roussy Institute
[8] University of Paris-Sud,Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute
[9] Odense University Hospital,Department of Oncology, Clinical Research Unit
[10] Hospital Ramón y Cajal,Cardiology Service
[11] Vall d’Hebron University Hospital,Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit
[12] Autonomous University of Barcelona,undefined
来源：
Advances in Therapy | 2013年 / 30卷
关键词：
Adverse effects; Antineoplastic agents/adverse effects; Cardiovascular; Dermatology; Medullary thyroid cancer; Medullary thyroid carcinoma; Patient safety; Piperidines/therapeutic use; Protein kinase inhibitors; Thyroid neoplasms/drug therapy; Vandetanib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：945 / 966
页数：21
相关论文
共 50 条
  • [1] Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
    Grande, Enrique
    Kreissl, Michael C.
    Filetti, Sebastiano
    Newbold, Kate
    Reinisch, Walter
    Robert, Caroline
    Schlumberger, Martin
    Tolstrup, Laerke K.
    Zamorano, Jose L.
    Capdevila, Jaume
    ADVANCES IN THERAPY, 2013, 30 (11) : 945 - 966
  • [2] Vandetanib and the management of advanced medullary thyroid cancer
    Campbell, Michael J.
    Seib, Carolyn D.
    Gosnell, Jessica
    CURRENT OPINION IN ONCOLOGY, 2013, 25 (01) : 39 - 43
  • [3] Role of vandetanib in the management of medullary thyroid cancer
    Brassard, Maryse
    Rondeau, Genevieve
    BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 59 - 66
  • [4] Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer
    Gillian M. Keating
    Katherine A. Lyseng-Williamson
    James E. Frampton
    BioDrugs, 2012, 26 (6) : 431 - 435
  • [5] VANDETANIB THERAPY IN MEDULLARY THYROID CANCER
    Grabowski, P.
    Briest, F.
    Baum, R. P.
    Zaknun, J. J.
    Kulkarni, H. R.
    Zeitz, M.
    Hoersch, D.
    DRUGS OF TODAY, 2012, 48 (11) : 723 - 733
  • [6] Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas
    Chougnet, Cecile N.
    Schlumberger, Martin
    Leboulleux, Sophie
    Baudin, Eric
    BULLETIN DU CANCER, 2014, 101 (09) : 891 - 895
  • [7] Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
    Deshpande, Hari
    Marler, Vicky
    Sosa, Julie Ann
    ONCOTARGETS AND THERAPY, 2011, 4 : 209 - 215
  • [8] Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience
    Kim, Mijin
    Yoon, Jee Hee
    Ahn, Jonghwa
    Jeon, Min Ji
    Kim, Hee Kyung
    Lim, Dong Jun
    Kang, Ho-Cheol
    Kim, In Joo
    Shong, Young Kee
    Kim, Tae Yong
    Kim, Bo Hyun
    ENDOCRINOLOGY AND METABOLISM, 2020, 35 (03) : 587 - 594
  • [9] Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
    Degrauwe, Nils
    Sosa, Julie Ann
    Roman, Sanziana
    Deshpande, Hari A.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6 : 243 - 252
  • [10] Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer
    Hu, Mimi I.
    Elisei, Rossella
    Dedecjus, Marek
    Popovtzer, Aron
    Druce, Maralyn
    Kapiteijn, Ellen
    Pacini, Furio
    Locati, Laura
    Krajewska, Jolanta
    Weiss, Richard
    Gagel, Robert F.
    ENDOCRINE-RELATED CANCER, 2019, 26 (02) : 241 - 250
12345